Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Go back to Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies| (NASDAQ: NRIX) | Delayed: 18.65 +1.10 (6.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.55 | 52 Week High | $ | |||
| Open | $17.83 | 52 Week Low | $ | |||
| Day High | $18.85 | P/E | N/A | |||
| Day Low | $17.83 | EPS | $ | |||
| Volume | 2,213,515 | |||||
